Dual PI3K/mTOR inhibitors: Does p53 modulate response?

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3719-3721

  Ekshyyan, Oleksandr ^a   Anandharaj, Arunkumar ^a   Nathan, Cherie Ann O ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ERLOTINIB; ISOENZYME; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; PROTEIN P73; PROTEIN S6; RAPAMYCIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; PYRIDONES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881185421     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1291     Document Type: Article

References (11)

1. Herzog A, Bian Y, Broek R Vander, Hall B, Coupar J, Cheng H, et al. PI3K-mTOR inhibitor PF-04691502 anti-tumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013; 19:3808-19.
2. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;6046:1157-60.
3. Shuttleworth SJ, Silva FA, Cecil ARL, Tomassi CD, Hill TJ, Raynaud FI, et al. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 2011;18:2686-714.
4. Cheng H, Bagrodia S, Bailey S, Edwards M, Hoffman J, Hu Q, et al. Discovery of highly potent PI3/mTOR dual inhibitor PF-04691502 through structure based drug design. Med Chem Commun 2010;1: 139-44.
5. Yuan J, Mehta PP, Yin M-J, Sun S, Zou A, Chen J, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 2011;10:2189-99.
6. Britten CD, Chow L, Conklin D, Kalous O, Desai A, Ginther C, et al. Abstract LB-70: In vitro anti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel of human breast cancer cell lines [abstract]. In: Proceedings of the 101st AACR Annual Meeting; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70:LB-70.
7. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, et al. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 2011;10:1440-9.
8. Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat 2013;138:369-81.
9. Millham R, Houk B, Borzillo G, LoRusso P, Marburg L, Britten C, et al. Abstract B163: First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA.Philadelphia(PA): AACR;MolCancerTher2011;10:B163.
10. ClinicalTrials.gov. Pre-operative study of PF-4691502 with letrozole compared to letrozole alone In patients with early breast cancer, 2012 [updated 2012 Dec]. Available from: http://clinicaltrials.gov/ct2/show/ NCT01430585.
11. Du W, Yi Y, Zhang H, Bergholz J, WuJ, Ying H, et al. Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy. PLoS ONE 2013;8:e63179.